There is significant overlap in the distributions of prodromal and control Parkinson’s patients even for the measure with the strongest signal. While some values for that measure seem to be almost conclusive markets of Parkinson’s, there are ranges in which the overlap is enough to make it not useful as a sole measure without having a high false positive rate.
Seems promising at catching a decent proportion of Parkinson’s super early, but I don’t think by itself this could yield both a good false positive and false negative rate. Keep in mind this is an ebullient press release summarizing a more conservative publication
There is significant overlap in the distributions of prodromal and control Parkinson’s patients even for the measure with the strongest signal. While some values for that measure seem to be almost conclusive markets of Parkinson’s, there are ranges in which the overlap is enough to make it not useful as a sole measure without having a high false positive rate.
Seems promising at catching a decent proportion of Parkinson’s super early, but I don’t think by itself this could yield both a good false positive and false negative rate. Keep in mind this is an ebullient press release summarizing a more conservative publication